To represent the clinical situation, we pursued our experiments in PC cells of different origins (MiaPaCa-2: primary tumor-derived; AsPC-1: metastatic site–derived) and with different levels of MYH expression (MiaPaCa-2: higher MYH expression; AsPC-1: lower MYH expression). This evidence concerns the gene MUTYH and pachyonychia congenita.